Reactivated ocular toxoplasmosis in a pregnant patient requires treatment decisions shaped by gestational stage. The standard approach used outside of pregnancy cannot be applied directly, because certain agents carry teratogenic risk or pose hazards to the newborn.
This protocol applies to pregnant patients experiencing reactivated ocular toxoplasmosis. Pregnancy is the defining factor in treatment selection: the appropriate therapeutic combination depends on which trimester the patient is in at the time of reactivation.
Management uses trimester-specific antiparasitic combinations, administered at reduced doses, with agent selection determined by fetal safety at each gestational stage. Certain agents that form part of classic treatment are contraindicated in this setting due to teratogenic potential or risk of neonatal harm.
Complete regimen detail, agent selection by trimester, and dosing are available in the full protocol below.